

In re: Schwarz  
Serial No.: 09/733,306  
Filed: December 8, 2000  
Page 2 of 6

### **Listing of Claims**

The list of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of facilitating vascular growth in cardiac muscle of a human subject in need of such treatment, comprising:  
inhibiting activity of EMAP II of SEQ ID NO:4 in said human subject by ~~an amount effective to stimulate vascular growth in said cardiac muscle, wherein said inhibiting step is not carried out by administering a human EMAP II antisense oligonucleotide~~ administering an antibody that specifically binds to EMAP II of SEQ ID NO:4.

2. (Currently Amended) The method according to claim 1, wherein said ~~inhibiting step is carried out by administering a compound that specifically binds to EMAP II of SEQ ID NO:4 to said subject in~~ antibody is administered in an amount effective to stimulate vascular growth in said cardiac muscle.

3-6. (Canceled)

7. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with myocardial ischemia.

8. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with atherosclerosis.

9. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with a myocardial disease.

10. (Previously Presented) The method according to claim 9, wherein said myocardial disease is cardiomyopathy or cardiac hypertrophy.

In re: Schwarz  
Serial No.: 09/733,306  
Filed: December 8, 2000  
Page 3 of 6

11. (Currently Amended) A method of facilitating vascular growth in cardiac muscle tissue of a human subject in need of such treatment, said method comprising:

administering to said human subject an active agent that inhibits activity of ~~EMAP II of SEQ ID NO:4 in said subject by~~ antibody that specifically binds to EMAP II of SEQ ID NO:4 in an amount effective to promote blood vessel formation in said cardiac muscle, ~~wherein said active agent is not a human EMAP II antisense oligonucleotide.~~

12-16. (Canceled)

17. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with myocardial ischemia.

18. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with atherosclerosis.

19. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with a myocardial disease.

20-46. (Canceled)

47. (New) The method of Claim 1, wherein the antibody is administered in a pharmaceutical formulation comprising the antibody that specifically binds to EMAP II of SEQ ID NO:4 and a pharmaceutically acceptable carrier.

48. (New) The method of Claim 11, wherein the antibody is administered in a pharmaceutical formulation comprising the antibody that specifically binds to EMAP II of SEQ ID NO:4 and a pharmaceutically acceptable carrier.